Zealand Pharma A/S
Research Zealand Pharma A/S (ZEAL) on Bullrun: market cap DKK 22.27B, P/E 8.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZEAL
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 22.27B
- P/E8.3
- Financial periodQ1 2026
- RevenueDKK 34.00M
- Net income-DKK 394.00M
- Free cash flow-DKK 683.00M
- Gross margin100.0%
Valuation Snapshot
latest market cap is DKK 22.27B; P/E is 8.3.
Peer valuation comparison
Latest P/E is 8.34x versus a Healthcare sector median of 24.46x (65.9% below).
Latest P/E is 8.34x versus a Denmark median of 19.06x (56.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 9.21B | DKK 6.46B | DKK 6.46B | 100.0% | n/a | DKK 4.58B | DKK 405.77M | DKK 14.83B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | DKK 22.27B | 8.3 | n/a | n/a |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zealand Pharma A/S's market cap?
Zealand Pharma A/S's market capitalization is DKK 22.27B.
What is Zealand Pharma A/S's P/E ratio?
Zealand Pharma A/S's price-to-earnings (P/E) ratio is 8.3.
What does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism.